Testis cancer

Postgraduate Medical Journal

Volumn 83, Issue 984, 2007, Pages 624-632

  Khan, Omar ^a   Protheroe, Andrew ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ESTROGEN; ETOPOSIDE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 12; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYPTORCHISM; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; EPIDIDYMITIS; ESTROGEN BLOOD LEVEL; FOLLOW UP; HERNIA; HUMAN; HYDROCELE; INCIDENCE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RISK FACTOR; SEMINOMA; SENSITIVITY AND SPECIFICITY; SPERM PRESERVATION; SPERMATOCELE; SURGICAL TECHNIQUE; SURVIVAL TIME; SYMPTOM; TESTIS BIOPSY; TESTIS CANCER; TESTIS TORSION; TREATMENT INDICATION; TREATMENT OUTCOME; VARICOCELE;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 35649002663     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.057992     Document Type: Review

References (56)

1. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2002 England. Series MB1 no.33. London: Office for National Statistics, 2005.
2. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5-11.
3. Garner MJ, Turner MC, Ghadirian P, et al. Epidemiology of testicular cancer: an overview. Int J Cancer 2005;116:331-9.
4. Lutke Holzik MF, Rapley EA, Crockford GP, et al. Genetic predisposition of to testicular germ-cell tumours. Lancet Oncol 2004;5:363-71.
5. Rapley EA, Crockford GP, Teare D, et al. Localization to Xq27 of a susceptibility gene for testicular germ cell tumours. Nat Genet 2000;24:197-200.
6. Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i (12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994;86:349-55.
7. Looijenga LH, de Munnik H, Oosterhuis JW. A molecular model for the development of germ-cell cancer. Int J Cancer 1999;83:809-14.
8. Bosl GJ, Motzer PJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-53.
9. Benson CB. The role of ultrasound in diagnosis and staging of testicular tumors. Semin Urol 1988;6:189-202.
10. Skinner EC, Skinner DG. Surgery of testicular neoplasms. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's urology, 7th ed.WB Saunders, 1998:3410-32.
11. Passarella M, Usta MF, Bivalacqua TJ, et al. Testicular-sparing surgery: a reasonable option in selected patients with testicular lesions. BJU International 2003;91:337-40.
12. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005;16:863-8.
13. Krege S, Souchon R, Schmoll HJ. German Testicular Cancer Study Group. Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur J Urol 2001;40:1962-68.
14. Horwich A. Testicular cancer. In: Horwich A, eds. Oncology - a multidisciplinary textbook. London: Chapman and Hall, 1995:485-98.
15. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
16. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol 2005;23:382s, [abstract].
17. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52.
18. Bamberg M, Schmidberger H, Meisner C, et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999;83:823-7.
19. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146-53.
20. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organization for the Research and Treatment of Cancer Trial 30942 [ISRCTN 18525328]. J Clin Oncol 2005;23:1200-8.
21. Oliver T, Dieckmann KP, Steiner H, et al. Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage I seminoma. J Clin Oncol 2005;23:395s, [abstract].
22. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293-300.
23. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101-6.
24. Garcia Del Muro X, Maroto P, Guma J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stages IIA/IIB testicular seminoma: a Spanish Germ Cell Cancer Group study. Proc Am Soc Clin Oncol 2004;23:388a [abstract].
25. Bosl GJ, Bajorin DF, Sheinfeld J, et al. Cancer of the testis. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 2005:1491-518.
26. Flechon A, Bompas E, Biron P, et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975-9.
27. Horwich A, Paluchowska A, Norman R, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997;8:37-40.
28. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma; an update of the prospective multicenter SEMPET trial. J Clin Oncol 2004;22:1034-9.
29. Albers P, Siener R, Kliesch S. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the german testicular cancer study group trial. J Clin Oncol 2003;21:1505-12.
30. Heidenreich A, Sesterhenn IA, Mostofi FK, et al. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998;83:1002-11.
31. Oliver RT, Ong J, Shamash J, et al. Long-term follow up of Anglian Germ Cell Cancer Group surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology 2004;63:556-61.
32. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000;163:1788-92.
33. Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urologic Oncology: Seminars and Original Investigations 2004;22:225-35.
34. Einhorn LH, Williams SD, Troner M, et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981;305:727-31.
35. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Eng J Med 1987;316:1435-40.
36. De Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or for cycles of bleomycin, etoposide, and ciplatinum chemotherapy and of a 3 or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:91-6.
37. Saxman SB, Finch D, Gonin R, et al. Long-term follow up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998;16:702-6.
38. Loehrer PJ, Johnson D, Elison P, et al. Importance of bleomycin in favorable prognosis disseminated germ-cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-6.
39. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good prognosis testicular nonseminom: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-43.
40. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-40.
41. Christian J, Huddart R, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003;21:871-7
42. Berney DM, Shamash J, Hendry WF, et al. Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided? Br J Cancer 2001;84:340-3.
43. Loehrer P, Gonin R, Nicols C, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500-4.
44. Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a Medical Research Council trial. Br J Cancer 2005;93:178-84.
45. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
46. Bhatia S, Abonour R, Porcu P, et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000;18:3346-51.
47. Pico J, Rosti G, Kramar A, et al. A randomized trial of high dose chemotherapy in the salvage treatment of patients failing first line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 2005;16:1152-9.
48. Huddart R, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment of testicular cancer. J Clin Oncol 2003;21:1513-23.
49. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-7.
50. Travis L, Curtis R, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
51. Fossa SD, Kravdal O. Fertility in Norwegian testicular cancer patients. Br J Cancer 2000;82:737-41.
52. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200-7.
53. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732-7.
54. Kollmansberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108-14.
55. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493-7.
56. Farmakis D, Pectasides D, Pectasides M, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor (G-CSF) as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor (GCT) patients: a phase II study. Proc Am Soc Clin Oncol 2004;23:389 Abstract, 4545.